Acute toxicity level 4 for Oral ingestion
https://www.ilo.org/legacy/english/protection/safework/ghs/g...
Defines Toxicity level 4 as ~ 2000 to < 5000 mg/kg
The most potent strain of "magic mushrooms" are at most ~2% by weight(Psilocybe azurescens)[0]. So according to all the de facto standard literature, a potentially fatal dose of magic mushrooms is over 3 ounces of dried mushroom per kilogram of body weight. At 68 kg I would need to ingest over 5 kg to come up to the lower bound of the LD50.
No one without an axe to grind could realistically argue toxicity is a real valid concern.
[0]https://www.shroomery.org/8700/Psilocybe-azurescens-taxonomy...
Those are not the measures we are concerned with when we're talking about uncommon or rare effects (which, like the Vioxx deaths, had an incidence of one in /thousands/ at standard dosages), or effects that manifest with /chronic/ usage (e.g., over years of use, as is common with anti-depressant therapy).
What you're discussing is apples to oranges.
As to safety, the LD50 of psilocybin is pretty well established at very high levels, with physical effects being unreported below that.
Poster: https://compasspathways.com/wp-content/uploads/2019/12/poste...
If you find the endless hype a source of optimism and hope, then ... well, I guess I /am/ glad you have another source of optimism and hope. I don't share it, though.
E.g., the company that did the major trials for ketamine actually studied the s-enantiomer of ketamine using a nasal spray, which is quite distinct from the years of data we've accumulated on racemic ketamine with prolonged IV infusion. But this let them get a patentable version of ketamine on the market.
They could get a “method of use” patent that describes treating a co diction with psilocybin.
Even without either of those, the FDA will give them 3 years of market exclusivity (no other drugs will be approved).
In this case, they went for a placebo set-up because they were also trying to grab a little data to show whether 25 mg was significantly distinct from 10mg. The comparison to placebo was not needed, but is winning them a little extra publicity.
Note also that the study probably include some regular visits to the hospital. Some people may eat more healthy food a few days before a blood exam so the doctor gets happier. Some people may change other habits, like no binge drinking. So you need to measure the results in a group that follow the same explicit and implicit rules.
Does the report of the symptoms use the same criteria in the study than in general population? What about dizziness? Does this produce dizziness? Does the general population report dizziness to their family doctor? Replace dizziness with chest pain, or constipation, or whatever symptom you are interested.
Also, people lie to their doctor because they try to be nice. It's not a voluntary lie, but if there is a study about curing something, people want to be nice and give optimistic feedback. You must have a double blind control group so you can compensate this.
This was a /phase one/ clinical trial.
Phase One: administer small doses under very close supervision in a tiny number of people to determine whether it's immediately dangerous, or safe enough /for further study/. They used 89 - initial randomization of 30 each to placebo, 10mg, and 25mg. That's a good number for a phase one trial. But when we look at the sort of things that start hurting people when released to market, they're the sort of adverse effects that go undetected in trials with thousands of participants, and would need an infeasible large trial (>10k patients) to detect.
This trial does not prove safety. This trial is meant to establish a dosing range that is /safe enough/ to participants to allow for further study. They found no "serious" adverse effects, in healthy volunteers - that is, not depressed patients. Can drugs like this have different effects in people w and without depression? Yes they most certainly can, in particular if those people are on concurrent medications (which they will be, since this is being developed for treatment-resistant depression).
“We wanted to look at the safety and tolerability profile of our psilocybin, and to look at the feasibility of a model where up to six one-to-one sessions are held at the same time." No they didn't /want/ to - they /had/ to. This is article is just a press release.
Phase 2 is generally a range of doses, within the range established in phase one, wherein we attempt to determine, to a rough level of accuracy, which doses show toxicity, which show therapeutic benefit, and at roughly what proportions. This phase is meant to determine what dose will be used in a phase 3 trial, if any dose exists with an appropriate proportion of therapeutic benefit to side effect.
Phase 3 - a dose (or couple of doses) of a drug in a regimen meant to reflect real-world proposed usage is distributed and compared against either a currently used drug or a placebo. Depending on how big an effect is expected, how common the disease, etc. we'd look at trials of hundreds to thousands of patients. This is the trial where we get a real sense of safety, side effect profiles, efficacy, etc. This is the make-or-break line for getting your drug to market.
Phase 4 "trial" - aftermarket surveillance. Goes on for years after a drug hits market, because there's no trial that comes to close to capturing the rare side effects that may be visible when applied to the general population.
This was, also, presented to a neuropsychopharm conference, not published data. Which is to say, they're ready to brag about it, but they're not ready to submit themselves to close scrutiny.